CGEN
Compugen Ltd. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website cgen.com
- Employees(FY) 69
- ISIN IL0010852080
Performance
+10.36%
1W
-11.98%
1M
+1.43%
3M
+212.41%
6M
+7.58%
YTD
+220.3%
1Y
Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Technical Analysis of CGEN 2024-05-03
Overview:
In analyzing the technical indicators for CGEN over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been showing an upward trend...
Recent News & Updates
- 2024-05-05 19:00
- 2024-04-24 19:00
- 2024-04-09 19:00
- 2024-04-02 19:00
- 2024-03-12 00:00
- 2024-03-10 19:00
- 2024-03-06 20:41
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript(Insidermonkey)
- 2024-03-05 18:00
- 2024-03-04 22:53
- 2024-03-04 18:16
Compugen: Q4 Earnings Snapshot(Yahoo Finance)
- 2024-03-04 18:00
- 2024-02-28 19:58
- 2024-02-25 18:00
- 2024-02-20 23:00
- 2024-02-19 18:00
- 2024-02-14 18:00
- 2024-01-07 18:05
- 2024-01-07 18:00
- 2023-12-18 21:11
Why Is Compugen (CGEN) Stock Up 189% Today?(Investorplace)
- 2023-12-18 18:10
- 2023-12-18 18:05
- 2023-12-18 18:00
- 2023-12-14 19:17
- 2023-12-04 20:40
- 2023-11-08 03:41
Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript(Yahoo Finance)
- 2023-11-06 18:28
Compugen: Q3 Earnings Snapshot(Yahoo Finance)
- 2023-11-06 18:00
Compugen Reports Third Quarter 2023 Results(Prnewswire)
- 2023-11-05 18:00
- 2023-11-03 04:35
- 2023-10-30 21:00
Page 1 of 4
previousnext